Prognostic Significance and Functional Role of CEP57 in Prostate Cancer

Siegel, 2013, Cancer statistics, 2013, CA Cancer J Clin, 63, 11, 10.3322/caac.21166 Schröder, 2014, Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, Lancet, 384, 2027, 10.1016/S0140-6736(14)60525-0 Tapia-Laliena, 2014, High-risk prostate cancer: a disease of genomic instability, Urol Oncol, 32, 1101, 10.1016/j.urolonc.2014.02.005 Duensing, 2005, A tentative classification of centrosome abnormalities in cancer, Cell Biol Int, 29, 352, 10.1016/j.cellbi.2005.03.005 Pihan, 2001, Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression, Cancer Res, 61, 2212 Cuevas, 2013, FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57, Cancer Res, 73, 1400, 10.1158/0008-5472.CAN-12-1857 Momotani, 2008, Cep57, a multidomain protein with unique microtubule and centrosomal localization domains, Biochem J, 412, 265, 10.1042/BJ20071501 Bossard, 2003, Translokin is an intracellular mediator of FGF-2 trafficking, Nat Cell Biol, 5, 433, 10.1038/ncb979 Balk, 2008, AR, the cell cycle, and prostate cancer, Nucl Recept Signal, 6, 10.1621/nrs.06001 Heinlein, 2004, Androgen receptor in prostate cancer, Endocr Rev, 25, 276, 10.1210/er.2002-0032 Yap, 2011, The changing therapeutic landscape of castration-resistant prostate cancer, Nat Rev Clin Oncol, 8, 597, 10.1038/nrclinonc.2011.117 Sharma, 2013, The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man, Cancer Cell, 23, 35, 10.1016/j.ccr.2012.11.010 Antonarakis, 2014, AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer, N Engl J Med, 371, 1028, 10.1056/NEJMoa1315815 Arora, 2013, Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade, Cell, 155, 1309, 10.1016/j.cell.2013.11.012 Thadani-Mulero, 2012, Androgen receptor on the move: boarding the microtubule expressway to the nucleus, Cancer Res, 72, 4611, 10.1158/0008-5472.CAN-12-0783 Piel, 2000, The respective contributions of the mother and daughter centrioles to centrosome activity and behavior in vertebrate cells, J Cell Biol, 149, 317, 10.1083/jcb.149.2.317 Emanuele, 2007, Xenopus Cep57 is a novel kinetochore component involved in microtubule attachment, Cell, 130, 893, 10.1016/j.cell.2007.07.023 Scher, 2012, Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, 367, 1187, 10.1056/NEJMoa1207506 Darshan, 2011, Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer, Cancer Res, 71, 6019, 10.1158/0008-5472.CAN-11-1417 Sailer, 2013, Comparison of p40 (ΔNp63) and p63 expression in prostate tissues—which one is the superior diagnostic marker for basal cells?, Histopathology, 63, 50, 10.1111/his.12116 Meunier, 2009, Pivotal role of translokin/CEP57 in the unconventional secretion versus nuclear translocation of FGF2, Traffic, 10, 1765, 10.1111/j.1600-0854.2009.00985.x Kavallaris, 2010, Microtubules and resistance to tubulin-binding agents, Nat Rev Cancer, 10, 194, 10.1038/nrc2803 Lukinavičius, 2013, Selective chemical crosslinking reveals a Cep57-Cep63-Cep152 centrosomal complex, Curr Biol, 23, 265, 10.1016/j.cub.2012.12.030 Corn, 2013, Targeting fibroblast growth factor pathways in prostate cancer, Clin Cancer Res, 19, 5856, 10.1158/1078-0432.CCR-13-1550 He, 2013, Cep57 protein is required for cytokinesis by facilitating central spindle microtubule organization, J Biol Chem, 288, 14384, 10.1074/jbc.M112.441501 Wu, 2012, Cep57, a NEDD1-binding pericentriolar material component, is essential for spindle pole integrity, Cell Res, 22, 1390, 10.1038/cr.2012.61 Cinnamon, 2009, Cellular contractility requires ubiquitin mediated proteolysis, PLoS One, 4, 10.1371/journal.pone.0006155 Sato, 2001, Correlation between centrosome abnormalities and chromosomal instability in human pancreatic cancer cells, Cancer Genet Cytogenet, 126, 13, 10.1016/S0165-4608(00)00384-8 Cunha-Ferreira, 2009, The SCF/Slimb ubiquitin ligase limits centrosome amplification through degradation of SAK/PLK4, Curr Biol, 19, 43, 10.1016/j.cub.2008.11.037 Habedanck, 2005, The Polo kinase Plk4 functions in centriole duplication, Nat Cell Biol, 7, 1140, 10.1038/ncb1320 Snape, 2011, Mutations in CEP57 cause mosaic variegated aneuploidy syndrome, Nat Genet, 43, 527, 10.1038/ng.822 Ruiz-Miró, 2011, Translokin (Cep57) interacts with cyclin D1 and prevents its nuclear accumulation in quiescent fibroblasts, Traffic, 12, 549, 10.1111/j.1600-0854.2011.01176.x Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747